Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 136 clinical trials
None
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The primary study

progesterone receptor
estrogen receptor
inflammatory breast cancer
erbb2
epidermal growth factor
  • 191 views
  • 01 Dec, 2021
  • 291 locations
None
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.

patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2-negative (HER2-negative) advanced/metastatic breast cancer.

  • 0 views
  • 05 Dec, 2021
  • 216 locations
None
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to

coronary artery disease
ceritinib
cancer
erbb2
epidermal growth factor
  • 212 views
  • 18 Nov, 2021
  • 129 locations
None
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

This multicenter, open-label, single-arm trial will evaluate the anti-tumor activity of ZW25 (zanidatamab) monotherapy in subjects with human epidermal growth factor receptor 2 (HER2)-amplified

  • 0 views
  • 22 Aug, 2021
  • 59 locations
None
A Study of ZN-c5 in Subjects With Breast Cancer

subjects with advanced estrogen receptor positive, human epidermal growth factor receptor 2 negative (ER+/HER2-) breast cancer. ZN-c5 will be evaluated both as monotherapy and in combination with

palbociclib
EGFR
estrogen receptor
growth factor
erbb2
  • 47 views
  • 20 Oct, 2021
  • 52 locations
None
  • 8 views
  • 05 Dec, 2021
  • 246 locations
None
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation

  • 10 views
  • 25 Nov, 2021
  • 86 locations
None
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

branches: PANSY-1 and PANSY-2. PANSY-1 is a study of hormone receptor (HR)-positive/human epidermal growth factor receptor-2 (HER2)-negative patients with 4 positive lymph node, while PANSY-2 is a study of

progesterone receptor
carboplatin
pertuzumab
estrogen receptor
erbb2
  • 2 views
  • 23 Jan, 2021
  • 1 location
None
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally recurrent inoperable or metastatic breast cancer. The primary hypotheses are that

progesterone receptor
estrogen receptor
erbb2
measurable disease
epidermal growth factor
  • 0 views
  • 05 Dec, 2021
  • 33 locations
None
Study of DF1001 in Patients With Advanced Solid Tumors

phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express human epidermal growth factor receptor 2 (HER2). Two combination therapy cohorts will be opened

renal function
pd-l1
cancer
measurable disease
pembrolizumab
  • 2 views
  • 24 Nov, 2021
  • 27 locations